2022
Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
Prunas O, Warren JL, Crawford FW, Gazit S, Patalon T, Weinberger DM, Pitzer VE. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. Science 2022, 375: eabl4292. PMID: 35084937, PMCID: PMC9261115, DOI: 10.1126/science.abl4292.Peer-Reviewed Original ResearchConceptsVaccine effectivenessSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Effectiveness of vaccinesEffectiveness of vaccinationTotal vaccine effectivenessSARS-CoV-2Household contactsSecond doseCoronavirus 2Household transmissionDelta variantDay 10VaccinationBNT162b2COVID-19InfectionChain binomial modelVaccineDoseImmunity
2025
Global estimates of rotavirus vaccine efficacy and effectiveness: a rapid review and meta-regression analysis
Prunas O, Asare E, Sajewski E, Li Y, Pithawala Z, Weinberger D, Warren J, Armah G, Cunliffe N, Iturriza-Gómara M, Lopman B, Pitzer V. Global estimates of rotavirus vaccine efficacy and effectiveness: a rapid review and meta-regression analysis. EClinicalMedicine 2025, 81: 103122. PMID: 40115174, PMCID: PMC11925534, DOI: 10.1016/j.eclinm.2025.103122.Peer-Reviewed Original ResearchRotavirus-associated gastroenteritisRotavirus vaccine efficacyPredicting vaccine efficacyVaccine efficacyVaccine effectivenessVaccine performanceNational rotavirus immunization programImpact of rotavirus vaccinationRotavirus immunization programAffecting young childrenBill &Meta-regression analysisRandomized controlled trialsSystematic review of studiesEstimates of vaccine effectivenessRotavirus morbidityMelinda Gates FoundationRotavirus vaccineCohort studyLicensed vaccinesVaccine trialsDecreased efficacyControlled trialsCase-controlLow-income settingsEstimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus
Xu H, Aparicio C, Wats A, Araujo B, Pitzer V, Warren J, Shapiro E, Niccolai L, Weinberger D, Oliveira C. Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus. JAMA Network Open 2025, 8: e250380. PMID: 40063022, PMCID: PMC11894488, DOI: 10.1001/jamanetworkopen.2025.0380.Peer-Reviewed Original ResearchConceptsRSV-positive casesCase-control studyRSV infectionLRTI-associated hospitalizationsWeeks postimmunizationLong-acting monoclonal antibodiesTest-negative case-control studyClinical settingRespiratory syncytial virusMultivariate logistic regressionYale New Haven Health SystemRSV diseaseEmergency department dataState immunization registryRSV seasonSyncytial virusNirsevimabPolymerase chain reactionClinical trialsLRTIInfantsPotential confoundersMonoclonal antibodiesBroader outcomesDisease severityEstimating the Serotype-Specific Association Between the Concentration of Vaccine-Induced Serum Antibodies and Protection Against Pneumococcal Colonization
Wong A, Warren J, Fitch L, Perniciaro S, Dagan R, Weinberger D. Estimating the Serotype-Specific Association Between the Concentration of Vaccine-Induced Serum Antibodies and Protection Against Pneumococcal Colonization. The Journal Of Infectious Diseases 2025, jiaf106. PMID: 40036886, DOI: 10.1093/infdis/jiaf106.Peer-Reviewed Original ResearchHigher-valent PCVsPneumococcal conjugate vaccinePneumococcal colonizationVaccine-induced serum antibodiesRisk of colonizationSerum immunoglobulin GRandomized controlled trialsConjugate vaccinePCV13Clinical trialsSerum IgGImmune responseVaccinated childrenSevere diseaseVaccine effectivenessSerum antibodiesPCV20Serotype-specificImmunoglobulin GSerotypesColonIndirect protectionIgGVaccineTrials
2024
Incorporating Incubation Period Distributions to Precisely Estimate the Association Between Rainfall and Legionella Infection
Cassell K, Warren J, Heneghan C, Weinberger D. Incorporating Incubation Period Distributions to Precisely Estimate the Association Between Rainfall and Legionella Infection. The Journal Of Infectious Diseases 2024, jiae625. PMID: 39689015, DOI: 10.1093/infdis/jiae625.Peer-Reviewed Original ResearchHeavy rainfallLegionnaires' diseaseSame-day exposureImpact of relative humidityLD casesStandard deviation increasePublic water supplyEstimate exposureRandom rainfallWater interactionsRainfallIncidence of LDWeather eventsWater supplyDeviation increaseIncreased riskLegionella infectionRainfall 2Absolute humidityRelative humidityLD riskBayesian modeling approachEstimated Population-Level Impact of Pneumococcal Conjugate Vaccines Against All-Cause Pneumonia Mortality Among Unvaccinated in 5 Latin American Countries
Prunas O, Shioda K, Toscano C, Bastias M, Valenzuela-Bravo M, Tito J, Warren J, Weinberger D, de Oliveira L. Estimated Population-Level Impact of Pneumococcal Conjugate Vaccines Against All-Cause Pneumonia Mortality Among Unvaccinated in 5 Latin American Countries. The Journal Of Infectious Diseases 2024, 230: e768-e776. PMID: 38502711, PMCID: PMC11481321, DOI: 10.1093/infdis/jiae144.Peer-Reviewed Original ResearchAll-cause pneumoniaPneumonia deathsPneumonia mortalityAge groupsPneumococcal conjugate vaccineProportion of IPD casesInvasive pneumococcal diseaseMulti-country studyIPD casesOlder age groupsPopulation-level impactMortality dataYears of ageInvasive pneumococcal disease casesConjugate vaccinePneumococcal conjugate vaccine introductionEffect of pneumococcal conjugate vaccinesTemporal trendsImpact of pneumococcal conjugate vaccinesUnvaccinated age groupsMortalityEvaluate changesPost-vaccination periodVaccine serotypesNo significant changes
2023
Incorporating Data from Multiple Endpoints in the Analysis of Clinical Trials: Example from RSV Vaccines
Prunas O, Willemsen J, Bont L, Pitzer V, Warren J, Weinberger D. Incorporating Data from Multiple Endpoints in the Analysis of Clinical Trials: Example from RSV Vaccines. Epidemiology 2023, 35: 103-112. PMID: 37793120, DOI: 10.1097/ede.0000000000001680.Peer-Reviewed Original ResearchIncorporating Efficacy Data from Initial Trials Into Subsequent Evaluations: Application to Vaccines Against Respiratory Syncytial Virus
Warren J, Sundaram M, Pitzer V, Omer S, Weinberger D. Incorporating Efficacy Data from Initial Trials Into Subsequent Evaluations: Application to Vaccines Against Respiratory Syncytial Virus. Epidemiology 2023, 35: 130-136. PMID: 37963353, PMCID: PMC10842163, DOI: 10.1097/ede.0000000000001690.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply